Breast Cancer Clinical Trial
Official title:
Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism Using a Limited Pharmacokinetic Sampling Plan
The goal of this clinical research study is to find out how gene expression (as well as how often this expression occurs) in patients with breast cancer affects how Xeloda® (capecitabine) is cleared (passed through the urine) from the body. The safety of capecitabine will also be studied.
Capecitabine, PK Testing, and DNA Analysis:
Capecitabine is designed to interfere with the growth of cancer cells, which may cause the
cells to die. It is cleared from the body by certain proteins (which are made from DNA--the
gene material of cells). Some patients have changes in these proteins that increase or
decrease the rate that capecitabine is cleared from the body.
Researchers will use pharmacokinetic (PK) testing and DNA analysis to learn how capecitabine
is cleared from your body. PK testing measures the amount of drug in the body at different
time points. Information learned in this study may help researchers decide the best doses of
capecitabine for future patients with breast cancer.
Screening Visit:
Before you can start treatment on this study, you will have about 2 teaspoons of blood drawn
for routine tests and to make sure that you are able to receive chemotherapy. This screening
blood test will help the study doctor decide if you are eligible to take part in this study.
Capecitabine Treatment:
If you are found to be eligible to take part in this study, you will be given capecitabine by
mouth on the day you choose to start this therapy. Your treating doctor will prescribe
capecitabine at a dose that is appropriate to treat the cancer. You can choose the start
date, excluding weekends, but will need to begin therapy in the morning of the day you
choose. You will have treatment with capecitabine even if you do not participate on this
study.
PK Testing and DNA Analysis:
You will have blood drawn (about 2 teaspoons each time) for PK testing and DNA analysis of
capecitabine at certain times throughout this study.
- For PK testing, blood will be drawn before your first dose of capecitabine, at 30, 60,
and 90 minutes after the first dose, and then at 2, 6, 8, and 10 hours after the first
dose.
- For DNA analysis, blood will only be drawn before you receive the first dose of
capecitabine.
If your dose changes, these PK blood tests may need to be repeated.
Length of Study:
You will remain on this study for up to 6 months, unless the disease gets worse, you
experience any intolerable side effects, or you decide to stop treatment with capecitabine.
This is an investigational study. Up to 100 patients will take part in this study. All will
be enrolled at M. D. Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |